Series BB venture round brings in $25mm for Aptus Endosystems

Aptus Endosystems Inc. (devices for endovascular aneurysm repair) has raised $25mm through its Series BB venture round. New backer Synergy Life Science Partners led (and gains a seat on the company’s board) and was joined by current shareholders US Venture Partners and Longitude Capital Management. Aptus will use the money to increase commercialization of its HeliFX aortic securement system in the US and Europe, where the product is already approved, and continue developing the device for unmet needs in aortic aneurysm treatment. The company is planning a US clinical trial to support PMA filing for its Fortevo abdominal aortic aneurysm endograft system; funds will also be used to broaden marketing across Europe, where it has the CE Mark.